Get the Stockscreener App
8.55
5.32%
-0.48
After Hours:
8.45
-0.10
-1.17%
Arvinas Inc Stock (ARVN) Latest News
Arvinas Plunges 40% After Pfizer-Partnered Drug Disappoints - MSN
Arvinas (NASDAQ:ARVN) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last? - Yahoo Finance
Bank of America Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Arvinas’s SWOT analysis: biotech stock faces pivotal trials amid competition - Investing.com
Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56% - Simply Wall St
Arvinas downgraded to Neutral from Buy at Goldman Sachs - TipRanks
Tesla To $120? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Pfizer, Arvinas post mixed late-stage trial results for breast cancer therapy - MSN
Arvinas stock draws Wedbush downgrade (ARVN:NASDAQ) - Seeking Alpha
Street View: Arvinas' breast cancer drug's trial results a letdown - TradingView
Arvinas price target lowered to $20 from $82 at BMO Capital - TipRanks
Arvinas (NASDAQ:ARVN) Receives "Buy" Rating from HC Wainwright - MarketBeat
Cautious Outlook on Arvinas Holding: Hold Rating Maintained Amid Mixed VERITAC-2 Trial Results - TipRanks
Oppenheimer Downgrades Arvinas (NASDAQ:ARVN) to Market Perform - MarketBeat
Arvinas Plunges 45% After Pfizer-Partnered Drug Disappoints - MSN
Mixed Phase III Results for Arvinas, Pfizer’s Breast Cancer PROTAC Degrader - Inside Precision Medicine
Arvinas and Pfizer’s vepdegestrant meets primary endpoint in VERITAC-2 trial - World Pharmaceutical Frontiers
Arvinas (NASDAQ:ARVN) Hits New 12-Month LowHere's Why - MarketBeat
ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study - Yahoo Finance
Arvinas stock holds Buy rating, $81 target from H.C. Wainwright By Investing.com - Investing.com Australia
Wedbush cuts Arvinas to Neutral as VERITAC-2 shows monotherapy strategy limited - TipRanks
BMO Capital cuts Arvinas stock target to $20 from $82 - Investing.com India
Arvinas stock holds Buy rating, $81 target from H.C. Wainwright - Investing.com India
BMO Capital cuts Arvinas stock target to $20 from $82 By Investing.com - Investing.com South Africa
Arvinas (NASDAQ:ARVN) Cut to "Neutral" at Wedbush - MarketBeat
Arvinas Holding’s Promising Phase 3 Results and Strategic Focus Support Buy Rating - TipRanks
Wedbush Downgrades Arvinas to Neutral From Outperform, Adjusts Price Target to $12 From $57 - Marketscreener.com
BofA lowers Arvinas price target to $28, calls selloff ‘overdone’ - TipRanks
Arvinas Holding Company: Strategic Positioning and Market Opportunities Amidst Challenges - TipRanks
BTIG maintains Buy on Arvinas stock, price target at $69 By Investing.com - Investing.com South Africa
Arvinas Holding Company: Promising ESR1m Subgroup Results and Strong Financial Position Support Buy Rating - TipRanks
Arvinas price target lowered to $26 from $60 at Wells Fargo - TipRanks
BTIG maintains Buy on Arvinas stock, price target at $69 - Investing.com
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Arvinas’ (ARVN) Buy Rating Reaffirmed at HC Wainwright - Defense World
Arvinas (NASDAQ:ARVN) Lowered to “Market Perform” Rating by Oppenheimer - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Contrasting Arvinas (NASDAQ:ARVN) & Elevai Labs (NASDAQ:ELAB) - Defense World
Arvinas shares halved as vepdegestrant underwhelms - The Pharma Letter
Citigroup Lowers Arvinas (NASDAQ:ARVN) Price Target to $19.00 - MarketBeat
Arvinas/Pfizer’s Vepdegestrant Misses Best Case In Phase III - Citeline News & Insights
Citi cuts Arvinas stock target to $10 from $19, maintains neutral - Investing.com
Arvinas stock rating cut to Perform at Oppenheimer By Investing.com - Investing.com Australia
Health: Pfizer-Arvinas' breast cancer treatment shows mixed results in late-stage study - Gulf Digital News
Why Pfizer's Cancer Partner Just Plummeted More Than 50% - Investor's Business Daily
Citi cuts Arvinas stock target to $10 from $19, maintains neutral By Investing.com - Investing.com South Africa
Arvinas Holding Company: Hold Rating Due to VERITAC-2 Trial Underperformance and Limited Market Uptake Potential - TipRanks
Arvinas price target lowered to $10 from $19 at Citi - TipRanks
Pfizer stock, Arvinas stock slip on breast cancer data (PFE:NYSE) - Seeking Alpha
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial - Benzinga
Promising Clinical Trial Results and Market Potential Drive Buy Rating for Arvinas Holding Company - TipRanks
Arvinas downgraded at Oppenheimer after trial misses co-primary endpoint - TipRanks
Arvinas gets positive breast cancer data, but finds differentiation a hard sell - BioPharma Dive
Crude Oil Gains 1%; Ciena Earnings Top Views - Benzinga
Arvinas stock rating cut to Perform at Oppenheimer - Investing.com India
Arvinas phase III wild card turns over in breast cancer - BioWorld Online
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients - Yahoo Finance
Arvinas shares tumble as breast cancer drug with Pfizer shows mixed results - Reuters
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):